Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Toxic

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    634 result(s) found for: Toxic. Displaying page 5 of 32.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-005398-73 Sponsor Protocol Number: 2007-005398-73 Start Date*: 2008-06-04
    Sponsor Name:Karolinska University Hospital
    Full Title: Treatment of malignant mesothelioma with pemetrexed (Alimta) + platinum (4 courses) or pemetrexed (Alimta) + platinum (4 courses) followed by Caelyx single drug (4 courses).
    Medical condition: Malignant pleural mesotelioma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027407 Mesothelioma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000098-35 Sponsor Protocol Number: ANEPRO_2016_78 Start Date*: 2017-07-31
    Sponsor Name:SERVICIO DE ANESTESIOLOGÍA Y REANIMACIÓN HOSPITAL UNIVERSITARIO LA PAZ
    Full Title: COMPARATIVE STUDY OF NAUTICS AND VOMITING IN THREE ANESTHETICAL REGIMENS: INTRAVENOUS, INHALATORY AND MIXED.
    Medical condition: Arthroscopy for Temporomandibular
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002359-14 Sponsor Protocol Number: 1.0 Start Date*: 2013-10-23
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intesnivmedizin und Schmerztherapie
    Full Title: Ultrasound Guided Caudal Blockade in Children between 30 and 50kg: A Feasibility Study
    Medical condition: Caudal block is a very well established method to anaesthesize children for lower body surgery until they have a body weight up to 25kg. We would like to prove that it is also possible to perfor...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003012-31 Sponsor Protocol Number: 2011RC23r Start Date*: Information not available in EudraCT
    Sponsor Name:DIRECTION CENTRALE DU SERVICE DE SANTE DES ARMEES
    Full Title: Cardiovascular effects of esmolol alone and in combination with levosimendan during septic shock
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004673-26 Sponsor Protocol Number: PDX-012 Start Date*: 2008-01-31
    Sponsor Name:Allos Therapeutics Inc.,
    Full Title: Protocol PDX-012: A Randomized, Phase 2b, Multi-center Study of Pralatrexate Versus Erlotinib in Patients with Stage IIIB/IV Non-small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-ba...
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066490 Progression of non small cell lung cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-003618-15 Sponsor Protocol Number: IRFMN-GBM-6272 Start Date*: 2013-09-17
    Sponsor Name:IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri"
    Full Title: Multicenter, randomized, non-comparative, open-label phase II trial on the efficacy of Ortataxel and Fotemustine in recurrent glioblastoma
    Medical condition: Glioblastoma in recurrence/progression after surgery (or biopsy), radiotherapy and chemotherapy with temozolomide
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005115-16 Sponsor Protocol Number: SU-011248 Start Date*: 2006-05-05
    Sponsor Name:Joaquim Bellmunt Molins
    Full Title: A phase ii study assesing su-011248 in previously untreated patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy Estudio fase II que evalúa la eficacia y tolerabilid...
    Medical condition: Previously untreated patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001104-21 Sponsor Protocol Number: ND-05006 Start Date*: 2009-01-28
    Sponsor Name:VU Cancer Centre, Afdeling Geneeskundige Oncologie
    Full Title: A PHASE I/II TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS (DELTA-24-RGD) ADMINISTERED BY CONVECTION ENHANCED DELIVERY IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
    Medical condition: Recurrent Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017101-11 Sponsor Protocol Number: Tem/Erlo in NSCLC-Pilotstudy Start Date*: 2010-09-08
    Sponsor Name:MUW, Klinik für Innere Medizin I, Onkologie
    Full Title: A Pilot Study of Erlotinib and Temsirolimus in Patients with Advanced Non-small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-based Treatment
    Medical condition: NSCLC
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004010-17 Sponsor Protocol Number: ANG206 Start Date*: 2004-12-09
    Sponsor Name:Amersham plc and its Amersham Health affiliates, trading as GE Healthcare
    Full Title: An open-label, multi-centre, phase 2a study to assess the feasibility and safety of intravenous bolus administration of 99mTc-NC100692 Injection in imaging metastases in late stage cancer patients.
    Medical condition: The subjects to be included in this study have been diagnosed with primary breast, lung (non-small cell), ovarian or prostate cancer or malignant melanoma and have metastatic spread of the cancer t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-004481-34 Sponsor Protocol Number: Uni-Koeln-1694 Start Date*: 2015-03-12
    Sponsor Name:University of Cologne
    Full Title: RANDOMIZED PHASE 2 TRIAL COMPARING EXPERIMENTAL IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 S.C.,GM-CSF) IN RECURRENT HIGH RISK NEUROBLASTOMA PATIENTS WITH STANDARD IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL...
    Medical condition: Recurrent, progressive or newly diagnosed high risk neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001502-10 Sponsor Protocol Number: GCTSK002 Start Date*: 2011-09-28
    Sponsor Name:National Cancer Institute
    Full Title: Phase II study of Everolimus in refractory testicular germ cell cancer.
    Medical condition: refractory metastatic germ cell tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-006371-67 Sponsor Protocol Number: RLBUHT 3729 Start Date*: 2009-09-10
    Sponsor Name:Royal Liverpool and Broadgreen University Hospital [...]
    1. Royal Liverpool and Broadgreen University Hospital
    2. University of Liverpool
    Full Title: EFFECT OF THIENOPYRIDINE DERIVATIVE (CLOPIDOGREL) ON THE DISPOSITION OF EFAVIRENZ AND NEVIRAPINE IN HIV POSITIVE PATIENTS
    Medical condition: To determine whether anti-platelet agent clopidigrel influences the disposition of NNRTIs (efavirenz and nevirapine)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002190-49 Sponsor Protocol Number: REO 008 Start Date*: 2006-11-08
    Sponsor Name:Oncolytics Biotech Inc
    Full Title: A Multi-Centre Single-Arm Phase II Study To Evaluate The Biological Effects Of Intratumoral Administration of Wild-Type Reovirus (REOLYSIN®) in Combination with Low Dose Radiation in Patients With ...
    Medical condition: Advanced or metastatic solid tumours that are refractory to standard therapy or for which no standard curative therapy exists
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003193-10 Sponsor Protocol Number: CDKO-125a-002 Start Date*: 2009-02-24
    Sponsor Name:Nerviano Medical Sciences S.r.l.
    Full Title: A phase I/II study of oral PHA-848125AC given daily for 14 consecutive days every 3 weeks in recurrent malignant glioma
    Medical condition: Phase I Part: Recurrent Malignant Glioma Phase II Part: Recurrent Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065443 Malignant glioma LLT
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-003001-85 Sponsor Protocol Number: BDD Start Date*: 2005-11-28
    Sponsor Name:Austrian Forum against Cancer
    Full Title: Bortezomib-Doxorubicin-Dexamethasone (BDD) as Treatment for Patients with Multiple Myeloma Presenting with Acute Renal Failure
    Medical condition: The occurrence of renal failure is an emergency situation in patients with multiple myeloma. A fast active relatively, non-toxic protocol seems presently the best option for attempts to reverse ren...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-003089-16 Sponsor Protocol Number: AGO-OVAR2.11 Start Date*: 2007-08-31
    Sponsor Name:AGO Research GmbH
    Full Title: Phase II trial in platinum-refractory ovarian cancer: a randomized multicenter trial with SU11248 to evaluate dosage, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine k...
    Medical condition: Platinum refractory or resistant ovarian cancer, primary cancer of the peritoneum or fallopian tube (defined as stable (SD) or progressive disease (PD) during platinum containing chemotherapy, or ...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000734-21 Sponsor Protocol Number: FL05-1 Start Date*: 2005-09-13
    Sponsor Name:Groupe d'Etude des Lymphomes de l'Adulte (GELA)
    Full Title: A Phase 2 Study of VELCADE™ in Subjects with Relapsed or Refractory follicular B-cell Lymphoma
    Medical condition: Follicular Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006144-55 Sponsor Protocol Number: ARD6123 [AVE0005B/2001] Start Date*: 2007-03-14
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A multicenter, open-label, single-arm, two-stage study of the efficacy and safety of AVE0005 (VEGF Trap) administered intravenously every 2 weeks in patients with platinum- and erlotinib-resistant,...
    Medical condition: patients with platinum- and erlotinib-resistant, locally advanced or metastatic non-small-cell lung adenocarcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-003554-15 Sponsor Protocol Number: 18031977 Start Date*: 2006-11-09
    Sponsor Name:National Cancer Institute
    Full Title: The histone deacetylase inhibitor (HDAC) valproic acid as second line treatment for hormone refractory metastatic prostate cancer. A phase II. study.
    Medical condition: hormone refractory metastatic prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 08:56:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA